Pulp Neuro Inc. is an early-stage biotechnology company incorporated in June 2026 by Lawrence T. Reiter, Ph.D. (Founder & CEO), Professor at Tulane University School of Medicine. The company is based in New Orleans with a planned transition to dedicated New Orleans BioInnovation Center lab space in Spring 2027, contingent on the anticipated NIH STTR award (due September 2026). We have developed a proprietary platform based on dental pulp stem cells (DPSC), purpose-built to de-risk preclinical drug discovery for rare neurogenetic disease. We do not develop therapeutics ourselves — we accelerate and de-risk the R&D of companies that do, by demonstrating that lead candidates works in patient-derived human neurons.